Company Profile | ![]() | 0-9 | ![]() | A | ![]() | B | ![]() | C | ![]() | D | ![]() | E | ![]() | F | ![]() | G | ![]() | H | ![]() | I | ![]() | J | ![]() | K | ![]() | L | ![]() | M | ![]() | N | ![]() | O | ![]() | P | ![]() | Q | ![]() | R | ![]() | S | ![]() | T | ![]() | U | ![]() | V | ![]() | W | ![]() | X | ![]() | Y | ![]() | Z |
WPP plc
(NYSE: WPP)
|
8:00 PM UTC, 04/24/25 | |||
---|---|---|---|---|
Last: $37.51 | Change: +1.05 | %Change: +2.88% | Volume: 231,490 |
11:09 AM EST, 02/12/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were treading water late Wednesday morning, edging 0.03% lower to 1,397.50 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and furniture maker Natuzzi (NTZ), which rose 3.4% and 2.5%, respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and financial services company Banco Santander (SAN), which were up 2% and 1.8%, respectively.
The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and biotech firm Evaxion Biotech (EVAX), which fell 8.9% and 4.3% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and petroleum refiner Equinor (EQNR), which dropped 4.2% and 3% respectively.
From the UK and Ireland, the gainers were led by insurance company Prudential (PUK) and biopharmaceutical company Verona Pharma (VRNA), which advanced 6.6% and 4.6% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Amarin (AMRN), which increased 2.7% and 2.3% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which lost 2.7% and 2.6% respectively. They were followed by utilities company National Grid (NGG) and communications company WPP (WPP), which were down 2% each.
http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.